Combined Antibody Screening for Celiac and Diabetes Evaluation

N/AEnrolling By InvitationNCT04677699

Pacific Northwest Research Institute64,410 enrolled

Overview

The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.

Study Type

OBSERVATIONAL

Enrollment

64,410

Conditions

Type 1 Diabetes Celiac Disease

Interventions

Combined Risk ScoreDIAGNOSTIC_TEST

Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Eligibility

Sex: ALLMin age: 1 DayMax age: 7 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Child must be between 0 to 8 months in age or between 4 to 7 years in age. Child must be born in the state of Washington. Exclusion Criteria: \-

Locations (1)

Pacific Northwest Research Institute

Seattle, Washington, United States

Outcomes

Primary Outcomes

Diagnosis of Type 1 Diabetes

Time frame: 5 years

Diagnosis of Celiac Disease

Time frame: 5 years

Secondary Outcomes

Severity of disease at diagnosis

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.